Shire (Pharmaceuticals) Overview
- Year Founded
-
1986
- Status
-
Acquired/Merged
- Employees
-
23,044
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$58.2B
Shire (Pharmaceuticals) General Information
Description
Manufacturer and marketer of specialty medicines intended to meet the needs of patients with rare diseases. The company specializes in developing products across core therapeutic areas including hematology, immunology, neuroscience, ophthalmic, internal medicine endocrine and hereditary angioedema.
Contact Information
Website
www.shire.comCorporate Office
- Block 2 & 3 Miesian Plaza
- 50-58 Baggot Street Lower
- Dublin 2
- Ireland
Corporate Office
- Block 2 & 3 Miesian Plaza
- 50-58 Baggot Street Lower
- Dublin 2
- Ireland
Shire (Pharmaceuticals) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 08-Jan-2019 | $58.2B | Completed | Generating Revenue | ||
| 5. Debt - Acquisition | 19-Sep-2016 | Completed | Generating Revenue | |||
| 4. Merger/Acquisition | 20-Oct-2014 | Cancelled | Generating Revenue | |||
| 3. PIPE | 20-Feb-2007 | Completed | Generating Revenue | |||
| 2. IPO | 15-Feb-1996 | Completed | Generating Revenue | |||
| 1. Early Stage VC | Completed | Generating Revenue |
Shire (Pharmaceuticals) Comparisons
Industry
Financing
Details
Shire (Pharmaceuticals) Competitors (62)
One of Shire (Pharmaceuticals)’s 62 competitors is CSL Behring (Biotechnology), a Corporation company based in Vienna, Austria.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CSL Behring (Biotechnology) | Corporation | Vienna, Austria | ||||
| Swedish Orphan Biovitrum | Formerly VC-backed | Stockholm, Sweden | ||||
| BioCryst Pharmaceuticals | Corporation | Durham, NC | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Biotest | Formerly PE-Backed | Dreieich, Germany |
Shire (Pharmaceuticals) Patents
Shire (Pharmaceuticals) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250099541-A1 | Compositions and methods for reducing oxidation of igf-1/igfbp | Pending | 19-Jan-2022 | ||
| US-20230181527-A1 | Apical sodium-dependent transporter inhibitor compositions | Pending | 26-Oct-2021 | ||
| WO-2022197758-A1 | Heteroaryl inhibitors of plasma kallikrein | Inactive | 17-Mar-2021 | ||
| WO-2022197755-A1 | Imidazopyridinyl inhibitors of plasma kallikrein | Inactive | 17-Mar-2021 | ||
| US-20240226106-A1 | Inhibitors of plasma kallikrein | Pending | 17-Mar-2021 | A61K31/53 |
Shire (Pharmaceuticals) Signals
Shire (Pharmaceuticals) Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| HealthCare Ventures | Venture Capital | Minority | ||
| Permira | PE/Buyout | Minority | ||
| SV Health Investors | PE/Buyout | Minority |
Shire (Pharmaceuticals) Investments & Acquisitions (53)
Shire (Pharmaceuticals)’s most recent deal was a Merger/Acquisition with Sanaplasma. The deal was made on 06-Sep-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sanaplasma | 06-Sep-2018 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| Certa Therapeutics | 04-Jun-2018 | Early Stage VC | Drug Discovery | ||
| Rani Therapeutics | 22-Dec-2017 | Later Stage VC | Drug Delivery | ||
| Radius Health | 30-Jun-2017 | Merger/Acquisition | Pharmaceuticals | ||
| OncoResponse | 23-Mar-2017 | Early Stage VC | Drug Discovery |
Shire (Pharmaceuticals) ESG
Risk Overview
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Shire (Pharmaceuticals) Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Shire Strategic Investment Group | Wayne, PA | 2011 | |
| Baxter International (Medical Equipment) | Deerfield, IL |
Shire (Pharmaceuticals) FAQs
-
When was Shire (Pharmaceuticals) founded?
Shire (Pharmaceuticals) was founded in 1986.
-
Where is Shire (Pharmaceuticals) headquartered?
Shire (Pharmaceuticals) is headquartered in Dublin, Ireland.
-
What is the size of Shire (Pharmaceuticals)?
Shire (Pharmaceuticals) has 23,044 total employees.
-
What industry is Shire (Pharmaceuticals) in?
Shire (Pharmaceuticals)’s primary industry is Pharmaceuticals.
-
Is Shire (Pharmaceuticals) a private or public company?
Shire (Pharmaceuticals) is a Private company.
-
What is the current valuation of Shire (Pharmaceuticals)?
The current valuation of Shire (Pharmaceuticals) is .
-
What is Shire (Pharmaceuticals)’s current revenue?
The current revenue for Shire (Pharmaceuticals) is .
-
How much funding has Shire (Pharmaceuticals) raised over time?
Shire (Pharmaceuticals) has raised $12.9B.
-
Who are Shire (Pharmaceuticals)’s investors?
HealthCare Ventures, Permira, and SV Health Investors have invested in Shire (Pharmaceuticals).
-
Who are Shire (Pharmaceuticals)’s competitors?
CSL Behring (Biotechnology), Swedish Orphan Biovitrum, BioCryst Pharmaceuticals, Merck & Co., and Biotest are some of the 62 competitors of Shire (Pharmaceuticals).
-
When was Shire (Pharmaceuticals) acquired?
Shire (Pharmaceuticals) was acquired on 08-Jan-2019.
-
Who acquired Shire (Pharmaceuticals)?
Shire (Pharmaceuticals) was acquired by Takeda Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process